Purchase this article with an account.
K.A. Yates, R.P. Kowalski, E.G. Romanowski, F.S. Mah, Y.J. Gordon; Linezolid and Daptomycin: Future Ophthalmic Antibiotics? . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1925.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We evaluated the in vitro antibacterial activity of linezolid and daptomycin, and compared those with the in vitro antibacterial activity of other commonly used ophthalmic antibiotics used for Gram–positive ocular infections.
The Minimum Inhibitory Concentrations (MICs) of 25 consecutive Staphylococcus aureus endophthalmitis isolates and 25 consecutive Coagulase–Negative Staphylococci (CNS) endophthalmitis isolates were determined for linezolid (LZ), daptomycin (DP), moxifloxacin (MX), gatifloxacin (GA), gentamicin (GM), oxacillin (OX), erythromycin (E), vancomycin (VA), and cephalothin (CP) using E–tests. Susceptibility was interpreted using the CLSI standards. MIC50 and MIC90 determinations are expressed as µg/ml.
Linezolid and daptomycin, along with vancomycin and cephalothin (cefazolin), demonstrated 100% in vitro susceptibility for the Staphylococcus aureus and Coagulase–Negative Staphylococci endophthalmitis isolates tested. Our results suggest that further studies to determine the full potential of these antibiotics in ophthalmology are warranted.
This PDF is available to Subscribers Only